CureVac said it will pursue European approval for its coronavirus vaccine candidate despite disappointing overall efficacy results, arguing that final analysis of its late-stage trial shows 77 per cent protection against severe disease and full protection against hospitalisation and death.
Earlier in June, shares in the German biopharmaceutical company fell by about 50 per cent after its interim data showed an overall efficacy of 47 per cent, far below that of rivals Moderna and BioNTech that also developed messenger ribonucleic acid (mRNA) jabs.
Final analysis by Nasdaq-listed CureVac showed overall efficacy of 48 per cent against Covid-19 of any severity, and 53 per cent against mild disease. In subjects between 18 and 60 years old, it said the higher efficacy against severe disease meant it still had a pathway for approval for its CVnCoV vaccine from the European Medicines Agency.
“In this final analysis, CVnCoV demonstrates a strong public health…